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In this paper we outline the current data capture systems for human immunodeficiency virus 
(HIV) and sexually transmitted infection (STI) surveillance used by Public Health England (PHE), 
and how these will be affected by the introduction of novel testing platforms and changing patient 
pathways. We outline the Chlamydia Online Clinical Care Pathway (COCCP), developed as part 
of the Electronic Self-Testing for Sexually Transmitted Infections (eSTI2) Consortium, which 
ensures that surveillance data continue to be routinely collected and transmitted to PHE. We 
conclude that both novel diagnostic testing platforms and established data capture systems must be 
adaptable to ensure continued robust public health surveillance.
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1. INTRODUCTION
Public Health England (PHE) collects comprehensive electronic surveillance data from a 
variety of sources. In the human immunodeficiency virus (HIV) and sexually transmitted 
infection (STI) Department, these include data on numbers of STI tests, diagnoses, and 
associated epidemiological information from sexual health services (GUMCAD), data on all 
chlamydia tests and outcomes from laboratories (CTAD), data on antimicrobial resistance 
patterns for gonorrhea from linked microbiological and clinical data (GRASP), data on HIV 
and AIDS reporting covering all service providers of English HIV outpatient services 
(HARS), and data on the number of patients who recently acquired HIV infection at the time 
of diagnosis (RITA). Consequently, England has timely, comprehensive and sophisticated 
HIV and STI surveillance systems, which compare favorably with those in other western 
industrialized countries.
Although internet requesting of STI sampling kits for home use is widely available in the 
UK, users return their samples to the laboratory for testing, and ongoing management 
follows traditional care pathways. Therefore, there is minimal impact on data acquisition for 
surveillance purposes. Similarly for HIV, pilots of an HIV self-sampling service accessed 
through the internet have proved very successful in the UK and this is now already 
considered part of standard of care.
New diagnostic test platforms, such as rapid tests and Point-of-Care (PoC) technologies, 
have the potential to be used in novel settings such as people’s homes (home or self-
sampling/self-testing). An HIV self-test was licensed in early 2014, and although there is as 
yet no CE-marked kit available on the market, there are both anticipated impacts on 
surveillance because of the difficulties in monitoring those who are being tested, as well as 
the challenge of ensuring positive results are linked into care services for confirmation, 
treatment and care. Data from England’s National Chlamydia Screening Programme (NCSP) 
show that 7% of chlamydia testing is internet-based, with high positivity of 11%, 
demonstrating the importance of being able to capture surveillance-related data from those 
being tested with new diagnostic technologies, for the meaningful assessment of testing 
patterns and trends in STI rates.
Harding-Esch et al. Page 2
DH15 (2015). Author manuscript; available in PMC 2016 January 05.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
2. CHANGING PATIENT PATHWAYS
Surveillance systems and their data sources will therefore need to adapt and be ready as 
these tests become cheaper, more accurate, and more widely available. This is particularly 
true if these tests become de-coupled from traditional care pathways. For example, the 
electronic self-testing for sexually transmitted infections (eSTI2) consortium aims to reduce 
the high impact of infectious diseases by linking the capacity to develop and implement 
simple to use, rapid, accurate tests for multiple infections which are affordable, reliable and 
can be mobile-phone networked, to on-line clinical care pathways (http://
www.esti2.org.uk/). Figure 1 depicts the current general patient pathways for sample 
collection, testing, and data transmission for surveillance purposes of STIs in England.
Self-sampling can be done either as part of a health care worker (HCW) consultation, or 
without HCW involvement. Samples from both these methods can be sent for established 
testing methods, at the clinic or direct to laboratories, where data are routinely transmitted to 
PHE (STI clinics to GUMCAD, laboratories to CTAD). However, a self-collected sample 
without a HCW can also be tested using novel rapid or PoC tests. These could become 
available through routine services, or they could be privately bought tests. Private market 
testing and diagnosis data are already not captured by existing surveillance systems, but the 
advent of novel sampling and testing methods could increase the size of the private market. 
Rapid and PoC testing, and increase in private market tests, will result in loss of data capture 
by PHE, unless they can be coupled with a new data capture system, such as an online 
clinical care pathway.
As part of eSTI2, the Chlamydia Online Clinical Care Pathway (COCCP) has been 
developed. This eClinical care pathway focuses on the UK’s most commonly diagnosed STI 
(Chlamydia trachomatis). The pathway enables people with genital chlamydia to receive 
their test result online, obtain information about the infection, complete a clinical 
consultation, and progress to receive a remote prescription of antibiotic treatment, within 
“eSexual Health clinics”, embedded within England’s National Health Service (NHS) sexual 
health services. An important part of the development of the eClinical Care Pathway 
Framework was ensuring that surveillance data continued to be routinely collected and 
transmitted to PHE. The COCCP was specifically designed to capture all data items 
routinely collected in traditional consultations for public health surveillance purposes and 
for the data to be captured through established mechanisms (GUMCAD for STI clinic data, 
and CTAD for laboratories). The system was also designed to be interoperable so that in the 
future, surveillance data could be fed directly from the COCCP to PHE and that data could 
be captured through information input via the internet, or into a mobile phone or other hand-
held device by the PoC test user. However, the success of such pathways will be dependent 
on the willingness of users to provide their data, particularly test-negative patients who 
would have no contact with services once they received their test result, and for whom 
surveillance data would need to be collected prior to receiving their test result.
Although there may be a risk that these new care pathways would cater for the “worried-
well”, they may also increase testing in high risk populations by removing barriers to testing 
in current traditional and outreach settings. The advent of new technologies may also make 
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data harder to interpret, as trends observed may result from changing population testing 
profiles as opposed to intrinsic changes in infection rates. Interpretation is further 
complicated by the need for identification and removal of duplicates (individuals tested 
more than once, for example, in community and clinical settings) once the data have been 
transmitted to PHE. Although deduplication is already an issue in existing surveillance 
systems, home sampling and testing will likely add to this problem as individuals test at 
home and then attend a more traditional setting for confirmatory testing. Identifying when 
confirmatory testing is taking place would have the additional advantage of verifying the 
initial PoC test result. Further, having a CE-mark does not guarantee that the test has high 
sensitivity or specificity. If there are no robust controls of tests available to buy for home- or 
self-testing, or pathways to confirm test result, patients may receive inaccurate diagnoses 
and management.
3. CONCLUSIONS
In conclusion, a critical concern for any established surveillance system currently dependent 
on data obtained from public sources, is the loss of data as individuals no longer engage with 
established services and are instead tested and managed remotely. If online self-testing, such 
as that described here, was commissioned by a public body, such as the National Health 
Service, public health monitoring would need to be part of the pathway. Mechanisms of data 
capture for surveillance purposes could also be incorporated into private market tests. There 
is flexibility in the existing surveillance structure to adapt to, and accommodate, novel tests 
and patient management systems. Engaging with those responsible for established STI/HIV 
surveillance would need to take place early on in the development of remote care pathways.
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Figure 1. 
Patient pathways involving established and novel sample collection, testing and data capture 
mechanisms.
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